智通财经APP获悉，荣昌生物(09995)早盘涨近5%，截至发稿，涨4.75%，报93.75港元，成交额2.26亿港元。
消息面上，荣昌生物宣布，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普(商品名：泰爱)用于治疗原发性免疫球蛋白A(IgA)肾病的上市申请，已获国家药品监督管理局药品审评中心(CDE)受理，并纳入优先审评程序。泰它西普成为IgA肾病领域首个申报上市的国产原研新药。
此外，9月23日，泰它西普的海外合作方VorBio宣布任命Navid Z.Khan博士为CMO。华泰证券指出，加盟前，Khan博士曾领导艾加莫德等创新药全球开发，在神经及自免领域沉淀深厚经验。泰它西普全球竞争力强劲，治疗MG具有BIC潜力，pSS领域为全球首款报产的创新药；叠加Khan博士的丰富经验，看好泰它西普全球开发前景。维持A股和H股“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.